Moderna (MRNA) shares surged 9.1% on Tuesday, climbing to $56.12 after FDA staff reviewers released briefing materials that deem the data supporting mFlusiva’s efficacy in adults 65 and older as adequate.
Regulatory Update Boosts Moderna Stock
The briefing arrived ahead of Thursday’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, where members will decide whether the benefits of mFlusiva outweigh its risks for individuals 50 years of age and older. FDA staff highlighted the absence of any “major deficiencies” in the submission, delivering the positive signal investors had been waiting for.
Implications for Investors and Market Outlook
Investors reacted swiftly, driving the share price toward its 52‑week high of $57.80. The rally also caught the eye of market participants who diversify into blockchain and crypto assets, underscoring the broader sentiment that favorable regulatory news can lift risk‑on positions across sectors.
Future Revenue Projections
Jefferies analyst Andrew Tsai interpreted the FDA staff’s assessment as a green light, projecting $750 million in combined U.S. influenza and COVID‑flu vaccine revenue by 2030. The forecast suggests that Moderna’s pipeline could sustain strong earnings growth, reinforcing its appeal to both traditional equity investors and those tracking emerging blockchain‑linked investment strategies.